Victoria Socha

DocwireNews

Down-titration, dose reduction or discontinuation, of renin-angiotensin-aldosterone system inhibitors (RAASi) is common following new-onset hyperkalemia. According to Hui Zhou, PhD, and colleagues, there are few data available on how RAASi down-titration is related to recurrent hyperkalemia.The researchers conducted a retrospective cohort study to examine recurrent hyperkalemia and factors associated with RAASi down-titration in patients with chronic kidney disease (CKD) and/or heart failure. Results were reported during a poster session at the American Society of Nephrology Kidney Week 2022 in a poster titled Recurrent Hyperkalemia and Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Down-Titration in a US Integrated Healthcare System.The study included adults with CKD and/or heart failure who experienced new-onset hyperkalemia at Kaiser Permanente Southern California. New-onset hyperkalemia was defined as potassium &ge;5.0 mEq/L. Eligible patients had two or more fills of RAASi within 1 year prior to the index. Patients were followed up for up to 1 year.Recurrent hyperkalemia was evaluated every 3 months from month 1 to month 9. Down-titration of RAASi was defined as &ge;90 day gap in refills of one or more RAASi (discontinuation) or &ge;25% dose reduction compared with the dose prior to the index. RAASi down-titration was evaluated in the following 3 months from month 4 to month 12. A secondary analysis using discontinuation as an outcome was also conducted. Factors associated with RAASi down-titration were identified using generalized estimating equation models.The study cohort included 7875 patients. Among those patients, the percentages of RAASi dose reduction were stable at 17% in all 3-month periods. Discontinuation decreased from 12% to 7% in the last 3 months.The percentage of recurrent hyperkalemia in the first month was 10%; the percentage in the last 3 months was 8%. There was an association between recurrent hyperkalemia and a higher likelihood of RAASi down-titration (rate ratio [RR], 1.36; 95% CI, 1.16-1.60) and discontinuation (RR, 1.75; 95% CI, 1.48-2.08). There was an association between inpatient recurrent hyperkalemia and worse kidney function and a higher likelihood of RAASi down-titration.&ldquo;After new-onset hyperkalemia, those who developed recurrent hyperkalemia were more likely to discontinue or reduce the dose of RAASi,&rdquo; the authors said.Source: Zhou H, Ni L, Sim JJ, et al. Recurrent hyperkalemia and renin-angiotensin-aldosterone system inhibitor (RAASi) down-titration in a US integrated healthcare system. FR-PO547. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2022; November 4, 2022; Orlando, Florida. Funding was provided by AstraZeneca.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Down-Titration of RAASI and Recurrent Hyperkalemia

Hyperkalemia

Down-titration, dose reduction or discontinuation, of renin-angiotensin-aldosterone system inhibitors (RAASi) is common following new-onset hyperkalemia. According to Hui ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe